Which is the better prognostic factor for resected non-small cell lung cancer: The number of metastatic lymph nodes or the currently used nodal stage classification?

Journal of Thoracic Oncology

Volumn 6, Issue 2, 2011, Pages 310-318

  Wei, Shenhai ^a,b   Asamura, Hisao ^a   Kawachi, Riken ^a   Sakurai, Hiroyuki ^a   Watanabe, Shun Ichi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b FIRST HOSPITAL OF TSINGHUA UNIVERSITY   (China)

Author keywords

Lymph node metastasis; Non small cell lung cancer; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; WEDGE RESECTION;

EID: 79551545979     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181ff9b45     Document Type: Article

References (25)

1. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-271.
2. Kang CH, Ra YJ, Kim YT, et al. The impact of multiple metastatic nodal stations on survival in patients with resectable N1 and N2 nonsmall-cell lung cancer. Ann Thorac Surg 2008;86:1092-1097.
3. Caldarella A, Crocetti E, Comin CE, et al. Prognostic variability among nonsmall cell lung cancer patients with pathologic N1 lymph node involvement. Epidemiological figures with strong clinical implications. Cancer 2006;107:793-798.
4. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000;18:2981-2989.
5. Riquet M, Manac'h D, Le Pimpec-Barthes F, et al. Prognostic significance of surgical-pathologic N1 disease in non-small cell carcinoma of the lung. Ann Thorac Surg 1999;67:1572-1576.
6. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer 1998;19:3-13.
7. Robinson LA, Ruckdeschel JC, Wagner H Jr, et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:243S-265S.
8. Misthos P, Sepsas E, Kokotsakis J, et al. The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer. Ann Thorac Surg 2008;86:1626-1630.
9. Fukui T, Mori S, Yokoi K, et al. Significance of the number of positive lymph nodes in resected non-small cell lung cancer. J Thorac Oncol 2006;1:120-125.
10. Misthos P, Sepsas E, Athanassiadi K, et al. Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg 2004;25:502-508.
11. Rusch VW, Crowley J, Giroux DJ, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:603-612.
12. Grunenwald D, Le Chevalier T. Re: Stage IIIA category of non-smallcell lung cancer: a new proposal. J Natl Cancer Inst 1997;89:88-89.
13. Asamura H, Suzuki K, Kondo H, et al. Where is the boundary between N1 and N2 stations in lung cancer? Ann Thorac Surg 2000;70:1839-1845; discussion 1845-1836.
14. Sobin LH, Gospodarowicz MK, Wittekind C. International Union Against Cancer (UICC). TNM Classification of Malignant Tumors. 7th Ed. Oxford, United Kingdom: Wiley-Blackwell, 2010.
15. Lee JG, Lee CY, Park IK, et al. Number of metastatic lymph nodes in resected non-small cell lung cancer predicts patient survival. Ann Thorac Surg 2008;85:211-215.
16. Asamura H, Nakayama H, Kondo H, et al. Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg 1999;117:1102-1111.
17. Okada M, Tsubota N, Yoshimura M, et al. Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal nodes in selective dissection. J Thorac Cardiovasc Surg 1998;116:949-953.
18. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
19. Asamura H, Goya T, Koshiishi Y, et al. A Japanese Lung Cancer Registry study: prognosis of 13, 010 resected lung cancers. J Thorac Oncol 2008;3:46-52.
20. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Gastric Cancer. V. 2. 2010. Available at: http://www.nccn.org/ professionals/physician-gls/PDF/gastric.pdf.
21. Watanabe S, Asamura H, Suzuki K, et al. The new strategy of selective nodal dissection for lung cancer based on segment-specific patterns of nodal spread. Interact Cardiovasc Thorac Surg 2005;4:106-109.
22. Watanabe S, Suzuki K, Asamura H. Superior and basal segment lung cancers in the lower lobe have different lymph node metastatic pathways and prognosis. Ann Thorac Surg 2008;85:1026-1031.
23. Watanabe S, Asamura H. Lymph node dissection for lung cancer: significance, strategy, and technique. J Thorac Oncol 2009;4:652-657.
24. Varlotto JM, Recht A, Nikolov M, et al. Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer. Cancer 2009;115:851-858.
25. Ludwig MS, Goodman M, Miller DL, et al. Postoperative survival and the number of lymph nodes sampled during resection of node-negative non-small cell lung cancer. Chest 2005;128:1545-1550.